 Terry Fry
Concepts (454)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 36 | 2025 | 295 | 9.050 |
Why?
| | T-Lymphocytes | 55 | 2025 | 1933 | 6.190 |
Why?
| | Antigens, CD19 | 24 | 2025 | 114 | 4.210 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2023 | 75 | 4.040 |
Why?
| | Graft vs Host Disease | 20 | 2023 | 240 | 3.690 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2024 | 278 | 3.180 |
Why?
| | CD8-Positive T-Lymphocytes | 19 | 2025 | 857 | 3.150 |
Why?
| | Hematopoietic Stem Cell Transplantation | 26 | 2023 | 572 | 3.120 |
Why?
| | Receptors, Antigen, T-Cell | 18 | 2023 | 704 | 2.840 |
Why?
| | Immunotherapy | 16 | 2024 | 592 | 2.790 |
Why?
| | Interleukin-7 | 23 | 2012 | 59 | 2.490 |
Why?
| | Dendritic Cells | 11 | 2016 | 479 | 2.460 |
Why?
| | Cancer Vaccines | 9 | 2018 | 164 | 1.960 |
Why?
| | CD4-Positive T-Lymphocytes | 11 | 2023 | 1056 | 1.870 |
Why?
| | Hematologic Neoplasms | 8 | 2023 | 140 | 1.830 |
Why?
| | Leukemia, Myeloid, Acute | 6 | 2025 | 592 | 1.820 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 8 | 2022 | 12 | 1.740 |
Why?
| | Lymphoma, B-Cell | 8 | 2025 | 105 | 1.720 |
Why?
| | Bone Marrow Transplantation | 9 | 2023 | 275 | 1.300 |
Why?
| | Lymphocyte Transfusion | 4 | 2017 | 20 | 1.270 |
Why?
| | Adoptive Transfer | 10 | 2019 | 218 | 1.170 |
Why?
| | Graft vs Leukemia Effect | 4 | 2017 | 12 | 1.030 |
Why?
| | Cytokines | 12 | 2022 | 2013 | 0.960 |
Why?
| | Neoplasms | 13 | 2023 | 2449 | 0.960 |
Why?
| | Dipeptides | 3 | 2014 | 47 | 0.950 |
Why?
| | Mice | 43 | 2025 | 16915 | 0.940 |
Why?
| | H-Y Antigen | 5 | 2013 | 7 | 0.930 |
Why?
| | T-Box Domain Proteins | 1 | 2025 | 96 | 0.910 |
Why?
| | Animals | 59 | 2025 | 35309 | 0.910 |
Why?
| | Antigens, Neoplasm | 5 | 2019 | 308 | 0.880 |
Why?
| | Graft vs Tumor Effect | 3 | 2021 | 8 | 0.840 |
Why?
| | Tumor Escape | 3 | 2021 | 39 | 0.760 |
Why?
| | Sialic Acid Binding Ig-like Lectin 3 | 1 | 2021 | 9 | 0.750 |
Why?
| | Humans | 107 | 2025 | 129271 | 0.740 |
Why?
| | Cell Adhesion Molecules | 1 | 2022 | 173 | 0.720 |
Why?
| | Receptors, Cytokine | 2 | 2024 | 35 | 0.720 |
Why?
| | Immune System | 5 | 2010 | 175 | 0.710 |
Why?
| | Cell Line, Tumor | 14 | 2025 | 3202 | 0.710 |
Why?
| | Perforin | 1 | 2020 | 19 | 0.700 |
Why?
| | Precursor Cells, B-Lymphoid | 2 | 2018 | 38 | 0.700 |
Why?
| | Leukemia | 5 | 2025 | 229 | 0.700 |
Why?
| | Thymus Gland | 6 | 2004 | 308 | 0.690 |
Why?
| | Retinal Neoplasms | 1 | 2020 | 26 | 0.680 |
Why?
| | Retinoblastoma | 1 | 2020 | 31 | 0.680 |
Why?
| | WT1 Proteins | 2 | 2018 | 14 | 0.680 |
Why?
| | Lymphoma | 2 | 2019 | 196 | 0.660 |
Why?
| | Recurrence | 13 | 2025 | 1005 | 0.660 |
Why?
| | Myelodysplastic Syndromes | 5 | 2023 | 129 | 0.650 |
Why?
| | Transplantation, Homologous | 9 | 2018 | 400 | 0.640 |
Why?
| | Adjuvants, Immunologic | 4 | 2014 | 221 | 0.630 |
Why?
| | T-Lymphocyte Subsets | 6 | 2023 | 412 | 0.630 |
Why?
| | Erythropoietin | 1 | 2020 | 88 | 0.620 |
Why?
| | Neoplasms, Experimental | 2 | 2019 | 170 | 0.610 |
Why?
| | Allergy and Immunology | 1 | 2019 | 42 | 0.610 |
Why?
| | Mice, Inbred C57BL | 17 | 2021 | 5439 | 0.580 |
Why?
| | Genetic Engineering | 2 | 2019 | 86 | 0.540 |
Why?
| | Boron Compounds | 2 | 2014 | 22 | 0.530 |
Why?
| | Hematopoietic Stem Cells | 4 | 2016 | 381 | 0.530 |
Why?
| | Calcitonin | 1 | 2016 | 27 | 0.530 |
Why?
| | Immunologic Memory | 8 | 2025 | 349 | 0.530 |
Why?
| | Cell Lineage | 2 | 2016 | 332 | 0.520 |
Why?
| | Child | 34 | 2023 | 20785 | 0.520 |
Why?
| | Cell Plasticity | 1 | 2016 | 27 | 0.510 |
Why?
| | Leukapheresis | 2 | 2017 | 21 | 0.500 |
Why?
| | Antigens, CD | 2 | 2017 | 489 | 0.500 |
Why?
| | Lymphocyte Activation | 11 | 2021 | 1109 | 0.500 |
Why?
| | Disease Models, Animal | 7 | 2020 | 4057 | 0.490 |
Why?
| | Donor Selection | 1 | 2015 | 75 | 0.470 |
Why?
| | Homeostasis | 6 | 2006 | 605 | 0.460 |
Why?
| | Mice, Knockout | 7 | 2020 | 2871 | 0.450 |
Why?
| | Apoptosis | 8 | 2019 | 2499 | 0.450 |
Why?
| | STAT1 Transcription Factor | 1 | 2014 | 70 | 0.450 |
Why?
| | Photopheresis | 2 | 2011 | 9 | 0.440 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 2 | 2014 | 45 | 0.440 |
Why?
| | Drug Resistance, Neoplasm | 5 | 2024 | 756 | 0.440 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2015 | 207 | 0.440 |
Why?
| | Rhabdomyosarcoma | 2 | 2014 | 64 | 0.430 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2025 | 812 | 0.430 |
Why?
| | Vaccination | 2 | 2012 | 1347 | 0.420 |
Why?
| | Recombinant Fusion Proteins | 4 | 2017 | 648 | 0.410 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2012 | 16 | 0.410 |
Why?
| | Boronic Acids | 1 | 2013 | 37 | 0.410 |
Why?
| | Lymphocyte Depletion | 8 | 2014 | 131 | 0.400 |
Why?
| | STAT3 Transcription Factor | 1 | 2014 | 194 | 0.400 |
Why?
| | Female | 48 | 2025 | 68556 | 0.390 |
Why?
| | Neoplasm Proteins | 1 | 2015 | 422 | 0.390 |
Why?
| | Flow Cytometry | 6 | 2020 | 1155 | 0.380 |
Why?
| | Siblings | 4 | 2014 | 215 | 0.380 |
Why?
| | Antigens, CD34 | 2 | 2011 | 88 | 0.380 |
Why?
| | Neurotoxicity Syndromes | 2 | 2024 | 23 | 0.370 |
Why?
| | Adult | 30 | 2025 | 35497 | 0.370 |
Why?
| | Mice, Inbred C3H | 4 | 2014 | 272 | 0.370 |
Why?
| | Young Adult | 18 | 2025 | 12392 | 0.370 |
Why?
| | Living Donors | 3 | 2014 | 286 | 0.360 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 29 | 0.360 |
Why?
| | Neoplasm, Residual | 3 | 2020 | 120 | 0.360 |
Why?
| | Antigen Presentation | 2 | 2009 | 207 | 0.350 |
Why?
| | Neoplasm Metastasis | 3 | 2016 | 610 | 0.350 |
Why?
| | Adolescent | 23 | 2025 | 20315 | 0.340 |
Why?
| | Receptors, Interleukin-7 | 5 | 2011 | 27 | 0.340 |
Why?
| | Signal Transduction | 7 | 2024 | 4926 | 0.340 |
Why?
| | Male | 39 | 2025 | 63517 | 0.330 |
Why?
| | Transplantation Conditioning | 4 | 2018 | 166 | 0.320 |
Why?
| | Lymphocyte Count | 4 | 2017 | 148 | 0.320 |
Why?
| | Gene Expression | 5 | 2020 | 1466 | 0.320 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2009 | 226 | 0.310 |
Why?
| | Receptors, Interferon | 1 | 2009 | 50 | 0.310 |
Why?
| | Interleukin-10 | 1 | 2011 | 300 | 0.310 |
Why?
| | Sarcoma, Ewing | 2 | 2012 | 88 | 0.300 |
Why?
| | Models, Immunological | 4 | 2020 | 95 | 0.300 |
Why?
| | Child, Preschool | 15 | 2023 | 10459 | 0.290 |
Why?
| | Clinical Trials as Topic | 4 | 2019 | 1004 | 0.290 |
Why?
| | Remission Induction | 4 | 2017 | 271 | 0.290 |
Why?
| | Monocytes | 1 | 2011 | 551 | 0.290 |
Why?
| | Social Adjustment | 1 | 2008 | 57 | 0.290 |
Why?
| | Mutation | 2 | 2015 | 3710 | 0.280 |
Why?
| | Killer Cells, Natural | 3 | 2021 | 427 | 0.280 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 252 | 0.270 |
Why?
| | Carcinoma | 1 | 2009 | 215 | 0.270 |
Why?
| | Receptors, Antigen | 2 | 2017 | 15 | 0.260 |
Why?
| | Allografts | 3 | 2018 | 136 | 0.260 |
Why?
| | Gene Rearrangement | 2 | 2024 | 148 | 0.260 |
Why?
| | Lymphopoiesis | 2 | 2006 | 25 | 0.260 |
Why?
| | Neuroblastoma | 2 | 2021 | 151 | 0.260 |
Why?
| | Prognosis | 7 | 2020 | 3773 | 0.250 |
Why?
| | Mice, Transgenic | 7 | 2021 | 2117 | 0.240 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2023 | 958 | 0.240 |
Why?
| | Interferon-gamma | 1 | 2009 | 772 | 0.240 |
Why?
| | Stem Cell Transplantation | 1 | 2006 | 164 | 0.240 |
Why?
| | Tissue Donors | 4 | 2018 | 391 | 0.240 |
Why?
| | Immunocompromised Host | 2 | 2010 | 198 | 0.240 |
Why?
| | Philadelphia Chromosome | 1 | 2024 | 18 | 0.230 |
Why?
| | HIV Infections | 5 | 2008 | 2721 | 0.230 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2025 | 39 | 0.230 |
Why?
| | Disease Progression | 5 | 2021 | 2630 | 0.230 |
Why?
| | Unrelated Donors | 3 | 2023 | 36 | 0.230 |
Why?
| | Transplantation, Autologous | 5 | 2018 | 211 | 0.230 |
Why?
| | Treatment Outcome | 12 | 2025 | 10202 | 0.230 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2025 | 220 | 0.220 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2024 | 71 | 0.220 |
Why?
| | Lentivirus | 3 | 2019 | 53 | 0.220 |
Why?
| | T-Lymphocytes, Regulatory | 4 | 2017 | 373 | 0.210 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 2 | 2014 | 21 | 0.210 |
Why?
| | Interleukin-15 | 4 | 2014 | 82 | 0.210 |
Why?
| | Combined Modality Therapy | 4 | 2021 | 1199 | 0.210 |
Why?
| | Regeneration | 2 | 2004 | 181 | 0.210 |
Why?
| | Macrophages | 1 | 2011 | 1484 | 0.210 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2023 | 46 | 0.200 |
Why?
| | Genetic Vectors | 3 | 2019 | 312 | 0.200 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2021 | 181 | 0.190 |
Why?
| | Mice, SCID | 4 | 2019 | 350 | 0.190 |
Why?
| | Burkitt Lymphoma | 1 | 2022 | 56 | 0.190 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2002 | 83 | 0.190 |
Why?
| | Microglia | 1 | 2024 | 232 | 0.190 |
Why?
| | Gangliosides | 1 | 2021 | 19 | 0.190 |
Why?
| | Lymphopenia | 4 | 2011 | 60 | 0.180 |
Why?
| | Thrombocytopenia | 1 | 2023 | 186 | 0.180 |
Why?
| | Coculture Techniques | 2 | 2012 | 223 | 0.180 |
Why?
| | Bone Marrow | 3 | 2020 | 271 | 0.180 |
Why?
| | Anxiety | 1 | 2008 | 962 | 0.180 |
Why?
| | Recovery of Function | 1 | 2005 | 641 | 0.180 |
Why?
| | Capillary Leak Syndrome | 1 | 2020 | 12 | 0.180 |
Why?
| | Exotoxins | 1 | 2020 | 15 | 0.180 |
Why?
| | Macrophage Activation Syndrome | 1 | 2020 | 21 | 0.170 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2021 | 70 | 0.170 |
Why?
| | Immunotoxins | 1 | 2020 | 54 | 0.170 |
Why?
| | Cyclophosphamide | 4 | 2023 | 232 | 0.170 |
Why?
| | Leukemia, B-Cell | 1 | 2020 | 13 | 0.170 |
Why?
| | B-Lymphocytes | 4 | 2018 | 815 | 0.170 |
Why?
| | Multiple Myeloma | 1 | 2021 | 125 | 0.170 |
Why?
| | Mice, Inbred NOD | 3 | 2019 | 588 | 0.170 |
Why?
| | Bacterial Toxins | 1 | 2020 | 104 | 0.170 |
Why?
| | Pediatrics | 1 | 2008 | 1049 | 0.170 |
Why?
| | Immunodominant Epitopes | 2 | 2012 | 28 | 0.160 |
Why?
| | Clinical Studies as Topic | 1 | 2019 | 6 | 0.160 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2021 | 124 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2019 | 11 | 0.160 |
Why?
| | Cell Proliferation | 6 | 2024 | 2375 | 0.160 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2019 | 17 | 0.160 |
Why?
| | Epitopes | 2 | 2018 | 470 | 0.160 |
Why?
| | Immunomodulation | 1 | 2019 | 92 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2012 | 1556 | 0.150 |
Why?
| | Cell Membrane | 2 | 2020 | 733 | 0.150 |
Why?
| | In Vitro Techniques | 1 | 2020 | 1085 | 0.150 |
Why?
| | Immunologic Factors | 1 | 2020 | 230 | 0.150 |
Why?
| | History, 21st Century | 1 | 2019 | 183 | 0.150 |
Why?
| | Cryopreservation | 1 | 2019 | 92 | 0.150 |
Why?
| | Down Syndrome | 1 | 2024 | 477 | 0.150 |
Why?
| | Follow-Up Studies | 5 | 2021 | 4887 | 0.150 |
Why?
| | Cell- and Tissue-Based Therapy | 2 | 2018 | 76 | 0.150 |
Why?
| | History, 20th Century | 1 | 2019 | 291 | 0.150 |
Why?
| | Autoantigens | 2 | 2019 | 419 | 0.150 |
Why?
| | Secondary Prevention | 1 | 2019 | 218 | 0.140 |
Why?
| | Membrane Proteins | 1 | 2004 | 1117 | 0.140 |
Why?
| | Protein Domains | 1 | 2019 | 253 | 0.140 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 631 | 0.140 |
Why?
| | Chromatin | 2 | 2023 | 478 | 0.140 |
Why?
| | Fas Ligand Protein | 2 | 2019 | 59 | 0.140 |
Why?
| | Cell Division | 3 | 2012 | 796 | 0.140 |
Why?
| | Graft Survival | 3 | 2011 | 511 | 0.140 |
Why?
| | Inflammation Mediators | 1 | 2020 | 505 | 0.140 |
Why?
| | Salvage Therapy | 2 | 2023 | 133 | 0.140 |
Why?
| | Cell Engineering | 1 | 2017 | 9 | 0.140 |
Why?
| | Cell Culture Techniques | 1 | 2019 | 336 | 0.140 |
Why?
| | Immunophenotyping | 2 | 2020 | 310 | 0.140 |
Why?
| | Lymph Nodes | 3 | 2013 | 470 | 0.130 |
Why?
| | Retrospective Studies | 9 | 2023 | 14461 | 0.130 |
Why?
| | Spine | 1 | 2018 | 157 | 0.130 |
Why?
| | Cytomegalovirus Infections | 1 | 2018 | 189 | 0.130 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 112 | 0.130 |
Why?
| | Stem Cell Research | 1 | 2016 | 1 | 0.130 |
Why?
| | Infant | 8 | 2018 | 8975 | 0.130 |
Why?
| | CD4 Lymphocyte Count | 4 | 2008 | 266 | 0.130 |
Why?
| | Receptors, Calcium-Sensing | 1 | 2015 | 6 | 0.130 |
Why?
| | Stem Cell Niche | 1 | 2016 | 53 | 0.130 |
Why?
| | Clone Cells | 1 | 2016 | 262 | 0.130 |
Why?
| | Antineoplastic Agents | 3 | 2019 | 2054 | 0.130 |
Why?
| | Gene Editing | 1 | 2016 | 67 | 0.120 |
Why?
| | PAX5 Transcription Factor | 1 | 2015 | 14 | 0.120 |
Why?
| | Aging | 3 | 2002 | 1774 | 0.120 |
Why?
| | Transcription Factors | 1 | 2023 | 1647 | 0.120 |
Why?
| | STAT Transcription Factors | 1 | 2015 | 14 | 0.120 |
Why?
| | Janus Kinases | 1 | 2015 | 12 | 0.120 |
Why?
| | Prospective Studies | 5 | 2023 | 7123 | 0.120 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2015 | 26 | 0.120 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 231 | 0.120 |
Why?
| | Cell Line | 2 | 2017 | 2779 | 0.120 |
Why?
| | Myeloid Cells | 1 | 2016 | 141 | 0.120 |
Why?
| | Receptors, Cell Surface | 1 | 2017 | 380 | 0.120 |
Why?
| | 4-1BB Ligand | 1 | 2014 | 7 | 0.120 |
Why?
| | Calgranulin A | 1 | 2014 | 4 | 0.120 |
Why?
| | Calgranulin B | 1 | 2014 | 7 | 0.120 |
Why?
| | Virus Replication | 1 | 2017 | 450 | 0.120 |
Why?
| | Models, Biological | 3 | 2009 | 1722 | 0.110 |
Why?
| | Growth | 1 | 1994 | 58 | 0.110 |
Why?
| | Erythrocytes | 1 | 2020 | 673 | 0.110 |
Why?
| | Survival Analysis | 2 | 2017 | 1269 | 0.110 |
Why?
| | Mice, 129 Strain | 1 | 2014 | 87 | 0.110 |
Why?
| | Growth Disorders | 1 | 1994 | 80 | 0.110 |
Why?
| | Genome | 1 | 2016 | 277 | 0.110 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2014 | 77 | 0.110 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2014 | 72 | 0.110 |
Why?
| | Phenotype | 4 | 2019 | 3074 | 0.110 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1247 | 0.110 |
Why?
| | Attitude to Health | 2 | 2008 | 430 | 0.110 |
Why?
| | Body Height | 1 | 1994 | 192 | 0.110 |
Why?
| | Alternative Splicing | 1 | 2015 | 216 | 0.110 |
Why?
| | Incidence | 2 | 2018 | 2636 | 0.110 |
Why?
| | Recombinant Proteins | 6 | 2011 | 1304 | 0.110 |
Why?
| | Transduction, Genetic | 3 | 2019 | 128 | 0.110 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2014 | 169 | 0.110 |
Why?
| | fas Receptor | 2 | 2019 | 95 | 0.100 |
Why?
| | Proteins | 1 | 2019 | 941 | 0.100 |
Why?
| | Animals, Congenic | 1 | 2012 | 9 | 0.100 |
Why?
| | Radiation Chimera | 1 | 2012 | 30 | 0.100 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2012 | 60 | 0.100 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2012 | 44 | 0.100 |
Why?
| | CD3 Complex | 3 | 2017 | 103 | 0.100 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2012 | 46 | 0.100 |
Why?
| | Tumor Burden | 1 | 2013 | 286 | 0.100 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2012 | 59 | 0.100 |
Why?
| | Treatment Failure | 2 | 2014 | 339 | 0.100 |
Why?
| | Tissue and Organ Procurement | 1 | 2016 | 288 | 0.100 |
Why?
| | Antigen-Presenting Cells | 2 | 2010 | 151 | 0.100 |
Why?
| | Chemokines | 1 | 2013 | 226 | 0.100 |
Why?
| | Body Weight | 2 | 2002 | 939 | 0.090 |
Why?
| | Interleukin-6 | 1 | 2015 | 720 | 0.090 |
Why?
| | Blood Component Removal | 1 | 2011 | 26 | 0.090 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 616 | 0.090 |
Why?
| | Brain Neoplasms | 2 | 2011 | 1143 | 0.090 |
Why?
| | CD4-CD8 Ratio | 2 | 2019 | 22 | 0.090 |
Why?
| | Methoxsalen | 1 | 2011 | 4 | 0.090 |
Why?
| | Spleen | 2 | 2011 | 506 | 0.090 |
Why?
| | Adenovirus Infections, Human | 1 | 2010 | 14 | 0.090 |
Why?
| | Cytosine | 1 | 2010 | 46 | 0.090 |
Why?
| | Alleles | 1 | 2013 | 845 | 0.090 |
Why?
| | Blood | 1 | 2011 | 105 | 0.090 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2002 | 267 | 0.080 |
Why?
| | Hematopoiesis | 3 | 2016 | 183 | 0.080 |
Why?
| | Organophosphonates | 1 | 2010 | 92 | 0.080 |
Why?
| | Antiviral Agents | 2 | 2018 | 712 | 0.080 |
Why?
| | Acute Disease | 3 | 2023 | 978 | 0.080 |
Why?
| | Transplantation Immunology | 1 | 2009 | 34 | 0.080 |
Why?
| | Sarcoma | 1 | 2011 | 176 | 0.080 |
Why?
| | Intestinal Neoplasms | 1 | 2009 | 28 | 0.080 |
Why?
| | Hematopoietic System | 1 | 2008 | 8 | 0.080 |
Why?
| | Virus Diseases | 1 | 2011 | 210 | 0.080 |
Why?
| | Cell Differentiation | 4 | 2023 | 1887 | 0.070 |
Why?
| | Interleukin-12 | 1 | 2009 | 118 | 0.070 |
Why?
| | Sibling Relations | 1 | 2008 | 10 | 0.070 |
Why?
| | Substrate Specificity | 1 | 2009 | 368 | 0.070 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2008 | 43 | 0.070 |
Why?
| | Ultraviolet Rays | 1 | 2011 | 382 | 0.070 |
Why?
| | Lymphocyte Subsets | 2 | 2014 | 84 | 0.070 |
Why?
| | Psychology | 1 | 2008 | 82 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2014 | 4077 | 0.070 |
Why?
| | Lipopolysaccharides | 1 | 2011 | 877 | 0.070 |
Why?
| | Biomarkers | 2 | 2016 | 3968 | 0.070 |
Why?
| | Skin Neoplasms | 1 | 2014 | 824 | 0.070 |
Why?
| | Tumor Cells, Cultured | 1 | 2009 | 942 | 0.070 |
Why?
| | Macaca fascicularis | 2 | 2007 | 62 | 0.070 |
Why?
| | Immune Tolerance | 2 | 2010 | 355 | 0.070 |
Why?
| | Brain | 1 | 2018 | 2669 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 232 | 0.060 |
Why?
| | Ki-67 Antigen | 2 | 2004 | 108 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2022 | 1036 | 0.060 |
Why?
| | Immunologic Surveillance | 1 | 2004 | 26 | 0.060 |
Why?
| | Middle Aged | 7 | 2025 | 31091 | 0.050 |
Why?
| | United States | 4 | 2018 | 13828 | 0.050 |
Why?
| | Nitriles | 1 | 2024 | 172 | 0.050 |
Why?
| | Hemostasis | 1 | 2004 | 79 | 0.050 |
Why?
| | Aged | 6 | 2025 | 22032 | 0.050 |
Why?
| | Obesity | 2 | 2022 | 2879 | 0.050 |
Why?
| | CD47 Antigen | 1 | 2023 | 28 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2024 | 275 | 0.050 |
Why?
| | Autoimmune Diseases | 1 | 2006 | 426 | 0.050 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 2002 | 15 | 0.050 |
Why?
| | Histocompatibility Testing | 2 | 2014 | 120 | 0.050 |
Why?
| | Cohort Studies | 3 | 2014 | 5409 | 0.050 |
Why?
| | United Kingdom | 2 | 2009 | 257 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2022 | 328 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2022 | 168 | 0.050 |
Why?
| | Pyrazoles | 1 | 2024 | 404 | 0.050 |
Why?
| | Body Mass Index | 1 | 2009 | 2272 | 0.050 |
Why?
| | Thymectomy | 1 | 2001 | 15 | 0.050 |
Why?
| | Protein Binding | 2 | 2019 | 2120 | 0.050 |
Why?
| | Pyrimidines | 1 | 2024 | 459 | 0.050 |
Why?
| | HIV Protease Inhibitors | 1 | 2001 | 68 | 0.040 |
Why?
| | Ritonavir | 1 | 2001 | 73 | 0.040 |
Why?
| | Cell Survival | 2 | 2019 | 1075 | 0.040 |
Why?
| | Skin Transplantation | 1 | 2001 | 84 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2011 | 2473 | 0.040 |
Why?
| | NF-kappa B | 1 | 2024 | 665 | 0.040 |
Why?
| | Lymphocytes | 1 | 2002 | 378 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2020 | 299 | 0.040 |
Why?
| | Subcutaneous Emphysema | 1 | 1999 | 1 | 0.040 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2019 | 9 | 0.040 |
Why?
| | Single-Chain Antibodies | 1 | 2019 | 17 | 0.040 |
Why?
| | Vulva | 1 | 1999 | 24 | 0.040 |
Why?
| | Mice, Nude | 1 | 2001 | 682 | 0.040 |
Why?
| | K562 Cells | 1 | 2019 | 86 | 0.040 |
Why?
| | Up-Regulation | 3 | 2008 | 839 | 0.040 |
Why?
| | Age Factors | 3 | 2011 | 3140 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2002 | 635 | 0.040 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 1999 | 21 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 263 | 0.040 |
Why?
| | Transgenes | 1 | 2019 | 177 | 0.040 |
Why?
| | Hallucinations | 1 | 2018 | 29 | 0.040 |
Why?
| | Mental Status and Dementia Tests | 1 | 2018 | 23 | 0.040 |
Why?
| | Immunization | 1 | 2001 | 411 | 0.040 |
Why?
| | Confusion | 1 | 2018 | 28 | 0.040 |
Why?
| | Cancer Care Facilities | 1 | 2018 | 32 | 0.040 |
Why?
| | Risk Factors | 4 | 2018 | 9746 | 0.040 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 122 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 186 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2019 | 286 | 0.040 |
Why?
| | Steroids | 1 | 2018 | 158 | 0.040 |
Why?
| | Gene Order | 1 | 2017 | 26 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 184 | 0.030 |
Why?
| | Weight Loss | 1 | 2002 | 732 | 0.030 |
Why?
| | Graft Rejection | 1 | 2001 | 598 | 0.030 |
Why?
| | Advisory Committees | 1 | 2018 | 216 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 390 | 0.030 |
Why?
| | Transfection | 1 | 2019 | 915 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2018 | 645 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 696 | 0.030 |
Why?
| | Cell Cycle | 1 | 2019 | 589 | 0.030 |
Why?
| | Time Factors | 4 | 2008 | 6543 | 0.030 |
Why?
| | Medical Oncology | 1 | 2018 | 270 | 0.030 |
Why?
| | Protein Engineering | 1 | 2017 | 106 | 0.030 |
Why?
| | Anti-HIV Agents | 1 | 2002 | 754 | 0.030 |
Why?
| | Ethics Committees, Research | 1 | 2016 | 41 | 0.030 |
Why?
| | Research Subjects | 1 | 2016 | 42 | 0.030 |
Why?
| | Serine-Arginine Splicing Factors | 1 | 2015 | 22 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2017 | 452 | 0.030 |
Why?
| | Genetic Therapy | 1 | 2017 | 288 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2008 | 5384 | 0.030 |
Why?
| | Health Policy | 1 | 2018 | 351 | 0.030 |
Why?
| | CD28 Antigens | 1 | 2015 | 48 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2018 | 5736 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2022 | 3080 | 0.030 |
Why?
| | Transplantation Chimera | 1 | 2014 | 54 | 0.030 |
Why?
| | Chimera | 1 | 2014 | 59 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 744 | 0.030 |
Why?
| | Exons | 1 | 2015 | 341 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2001 | 2716 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 256 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2015 | 437 | 0.030 |
Why?
| | Transcriptome | 1 | 2019 | 874 | 0.030 |
Why?
| | Reference Values | 1 | 1994 | 793 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 776 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2016 | 379 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2015 | 387 | 0.020 |
Why?
| | Vidarabine | 1 | 2012 | 30 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 785 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 2014 | 242 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 87 | 0.020 |
Why?
| | Etoposide | 1 | 2012 | 148 | 0.020 |
Why?
| | Vincristine | 1 | 2012 | 108 | 0.020 |
Why?
| | Rituximab | 1 | 2012 | 164 | 0.020 |
Why?
| | Prednisone | 1 | 2012 | 233 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2014 | 867 | 0.020 |
Why?
| | Doxorubicin | 1 | 2012 | 328 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2009 | 49 | 0.020 |
Why?
| | Biomedical Research | 1 | 2016 | 637 | 0.020 |
Why?
| | Bone Neoplasms | 1 | 2012 | 231 | 0.020 |
Why?
| | Bacteremia | 1 | 2011 | 194 | 0.020 |
Why?
| | Opportunistic Infections | 1 | 2009 | 46 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1416 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 851 | 0.020 |
Why?
| | Risk | 1 | 2011 | 854 | 0.020 |
Why?
| | CD8 Antigens | 1 | 2008 | 76 | 0.020 |
Why?
| | Leukocytes | 1 | 2010 | 306 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2015 | 2703 | 0.020 |
Why?
| | Cell Separation | 1 | 2008 | 316 | 0.020 |
Why?
| | HLA Antigens | 1 | 2008 | 234 | 0.020 |
Why?
| | HIV | 1 | 2008 | 227 | 0.020 |
Why?
| | Mass Screening | 1 | 1994 | 1149 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3386 | 0.020 |
Why?
| | Cell Polarity | 1 | 2007 | 139 | 0.020 |
Why?
| | Body Composition | 1 | 2009 | 649 | 0.020 |
Why?
| | Catheter Ablation | 1 | 2009 | 335 | 0.020 |
Why?
| | Forkhead Transcription Factors | 1 | 2006 | 184 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2006 | 302 | 0.010 |
Why?
| | Adiposity | 1 | 2009 | 504 | 0.010 |
Why?
| | Annexin A5 | 1 | 2004 | 23 | 0.010 |
Why?
| | Interleukins | 1 | 2006 | 241 | 0.010 |
Why?
| | Coloring Agents | 1 | 2004 | 77 | 0.010 |
Why?
| | Stromal Cells | 1 | 2004 | 105 | 0.010 |
Why?
| | Macaca mulatta | 1 | 2004 | 149 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1839 | 0.010 |
Why?
| | Tissue Distribution | 1 | 2004 | 315 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 854 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 1949 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2009 | 803 | 0.010 |
Why?
| | bcl-2-Associated X Protein | 1 | 2002 | 55 | 0.010 |
Why?
| | Models, Genetic | 1 | 2004 | 593 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 2001 | 17 | 0.010 |
Why?
| | Temperature | 1 | 2004 | 634 | 0.010 |
Why?
| | Leukocyte Common Antigens | 1 | 2001 | 82 | 0.010 |
Why?
| | Kinetics | 1 | 2004 | 1644 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 336 | 0.010 |
Why?
| | Colon | 1 | 2002 | 252 | 0.010 |
Why?
| | Pubic Bone | 1 | 1999 | 6 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1202 | 0.010 |
Why?
| | Risk Assessment | 1 | 2008 | 3233 | 0.010 |
Why?
| | Genotype | 1 | 2004 | 1835 | 0.010 |
Why?
| | Hyperbaric Oxygenation | 1 | 1999 | 38 | 0.010 |
Why?
| | Radiography, Abdominal | 1 | 1999 | 46 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2009 | 2003 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2004 | 1367 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2007 | 5051 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1839 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 1999 | 2515 | 0.000 |
Why?
|
|
Fry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|